Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IONS
stocks logo

IONS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
152.57M
-32.79%
-1.197
+178.15%
188.91M
+43.11%
-0.557
-39.79%
210.36M
-53.46%
-0.517
-161.06%
Estimates Revision
The market is revising Upward the revenue expectations for Ionis Pharmaceuticals, Inc. (IONS) for FY2025, with the revenue forecasts being adjusted by 3.72% over the past three months. During the same period, the stock price has changed by 33.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-14.9%
In Past 3 Month
Stock Price
Go Up
up Image
+33.61%
In Past 3 Month
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.83 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.83 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 81.810
sliders
Low
65.00
Averages
84.83
High
110.00
Current: 81.810
sliders
Low
65.00
Averages
84.83
High
110.00
H.C. Wainwright
Buy
maintain
$100 -> $110
2025-11-10
Reason
H.C. Wainwright
Price Target
$100 -> $110
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ionis Pharmaceuticals to $110 from $100 and keeps a Buy rating on the shares. The firm believes Olezarsen is positioned to become the new standard for severe hypertriglyceridemia.
Piper Sandler
Overweight
maintain
$70 -> $77
2025-11-04
Reason
Piper Sandler
Price Target
$70 -> $77
2025-11-04
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Ionis Pharmaceuticals to $77 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported a solid Q3 print with total revenue of $157M, including $32M from Tryngolza sales. Piper commend this name's recent commercial execution and continue to like the set-up on shares given near- and intermediate-term portfolio expansion opportunities across wholly owned and partnered assets.
TD Cowen
Buy
upgrade
$59 -> $99
2025-10-30
Reason
TD Cowen
Price Target
$59 -> $99
2025-10-30
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ionis Pharmaceuticals to $99 from $59 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results driven by Tryngolza beat/raise. Cowen is adding $1.5B in peak global sales to theirmodel at $25k/yr.
Morgan Stanley
Tryngolza
Overweight
maintain
$90 -> $94
2025-10-30
Reason
Morgan Stanley
Tryngolza
Price Target
$90 -> $94
2025-10-30
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Ionis Pharmaceuticals to $94 from $90 and keeps an Overweight rating on the shares after "another strong quarter" in Q3, highlighted by Tryngolza in FCS outperforming again and driving a third guidance raise for the year. The firm expects detailed SHTG data at the upcoming AHA meeting on November 8 to "further strengthen the profile," the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$95 -> $100
2025-10-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$95 -> $100
2025-10-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ionis Pharmaceuticals to $100 from $95 and keeps a Buy rating on the shares. The firm recommends buying the shares of the American Heart Association meeting next month. The firm sees a potential $4B sales opportunity for olezarsen. Talks with management suggest "deeper efficacy, wider reach, and defensible mid-teens pricing," the analyst tells investors in a research note.
Barclays
Overweight
maintain
$80 -> $95
2025-10-30
Reason
Barclays
Price Target
$80 -> $95
2025-10-30
maintain
Overweight
Reason
Barclays raised the firm's price target on Ionis Pharmaceuticals to $95 from $80 and keeps an Overweight rating on the shares. The company reported a second consecutive beat quarter for Tryngolza and raised 2025 revenue guidance, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ionis Pharmaceuticals Inc (IONS.O) is -30.11, compared to its 5-year average forward P/E of -25.45. For a more detailed relative valuation and DCF analysis to assess Ionis Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-25.45
Current PE
-30.11
Overvalued PE
-1.80
Undervalued PE
-49.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-16.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-7.16
Undervalued EV/EBITDA
-25.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.54
Current PS
0.00
Overvalued PS
11.62
Undervalued PS
7.45
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 242.57% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IONS News & Events

Events Timeline

(ET)
2025-12-02
07:10:00
Ionis Receives FDA Breakthrough Therapy Designation for Zilganersen in Alexander Disease
select
2025-12-01 (ET)
2025-12-01
07:19:00
Ionis Pharmaceuticals' Olezarsen Receives FDA Breakthrough Therapy Designation
select
2025-11-14 (ET)
2025-11-14
07:42:44
Ionis Pharmaceuticals Receives Positive CHMP Opinion for Dawnzera Approval
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02NASDAQ.COM
PinnedIonis Pharma's Zilganersen Receives Breakthrough Therapy Designation from FDA

  • FDA Breakthrough Therapy Designation: Ionis Pharmaceuticals has received Breakthrough Therapy designation from the FDA for zilganersen, aimed at treating Alexander disease (AxD).

  • Clinical Study Support: The designation is based on positive topline results from a pivotal study involving children and adults with genetically confirmed Alexander disease.

  • Future Plans: Ionis intends to submit a New Drug Application (NDA) to the FDA in the first quarter of 2026.

  • Expanded Access Program: The company is also planning to initiate an Expanded Access Program in the U.S. for patients with Alexander disease.

[object Object]
Preview
9.0
12-03Benzinga
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data

  • Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.

  • Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.

  • Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.

  • Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.

[object Object]
Preview
9.0
12-02Newsfilter
Ionis Receives FDA Breakthrough Therapy Designation for Zilganersen, NDA Submission Planned for Q1 2026
  • Breakthrough Therapy Designation: Ionis' zilganersen has received Breakthrough Therapy designation from the FDA for treating Alexander disease, a rare and often fatal neurological condition, marking a significant advancement in treatment options.
  • Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a 33.3% improvement in gait speed at week 61, indicating its potential to enhance patient functionality with statistically significant results.
  • Future Plans: Ionis plans to submit a New Drug Application (NDA) to the FDA in Q1 2026 and initiate an Expanded Access Program to expedite access for patients in urgent need of treatment.
  • Market Outlook: This designation not only enhances Ionis' innovative profile in the neurology sector but also positions the company for significant revenue growth and long-term value creation, especially in a market lacking effective treatment options.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ionis Pharmaceuticals Inc (IONS) stock price today?

The current price of IONS is 81.81 USD — it has decreased -0.04 % in the last trading day.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s business?

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

arrow icon

What is the price predicton of IONS Stock?

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.83 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s revenue for the last quarter?

Ionis Pharmaceuticals Inc revenue for the last quarter amounts to 156.72M USD, increased 17.12 % YoY.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s earnings per share (EPS) for the last quarter?

Ionis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.80 USD, decreased -15.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ionis Pharmaceuticals Inc (IONS)'s fundamentals?

The market is revising Upward the revenue expectations for Ionis Pharmaceuticals, Inc. (IONS) for FY2025, with the revenue forecasts being adjusted by 3.72% over the past three months. During the same period, the stock price has changed by 33.61%.
arrow icon

How many employees does Ionis Pharmaceuticals Inc (IONS). have?

Ionis Pharmaceuticals Inc (IONS) has 1069 emplpoyees as of December 05 2025.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS) market cap?

Today IONS has the market capitalization of 13.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free